Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms

NCT04858893 | Completed

• 1 other identifier: CoMDA
• Study Type: observational
• Target: 562
• Locations: 1 country
• Sites: 1

Brief Summary

Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in Movement Disorders Assessment) is developed by merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery (FAB). A machine learning, able to classify the cognitive profile and predict patients' at risk of dementia, is created.

Conditions

Primary Parkinsonism; Secondary Vascular Parkinson Disease; Multiple System Atrophy; Supranuclear Palsy, Progressive

Outcome Measures

Primary Outcomes (1)

• Neural Net 91 classificator from CoMDA score

  prediction of cognitive level obtained from the application of Neural Net 91 classificator at CoMDA score

  30 minuts

Study Arms (2)

Subjects affected from Parkinsonims

Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator

Diagnostic Test: CoMDA associated with Neural Net 91 classificator

Health Controls

CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator

Diagnostic Test: CoMDA associated with Neural Net 91 classificator

Interventions

CoMDA associated with Neural Net 91 classificator DIAGNOSTIC_TEST

Health Controls; Subjects affected from Parkinsonims

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

500 subjects suffering from different forms of Parkinson Disease or Atypical Parkinsonims Syndorme and 61 Helathy Controls

You may qualify if:

• diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria (Postuma et al. 2015); b) diagnosis of PSP according to the MDS clinical diagnostic criteria (Höglinger et al. 2017); c) diagnosis of MSA according to the second diagnostic consensus statement (Gilman et al. 2008); d) diagnosis of VP according to Zijlmans et al (Zijlmans et al. 2004).

You may not qualify if:

• a) any focal brain lesion detected with brain imaging studies (CT or MRI); b) diagnosis of clinically relevant psychiatric disorders, psychosis (evaluated with Neuropsychiatric Inventory) and/or delirium; c) diagnosis of dementia or MCI; d) diagnosis of neurological diseases other than PD or atypical parkinsonian syndromes; e) other medical conditions negatively affecting the cognitive status; f) disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific items of MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III, such as to affect the psychometric evaluation; g) disturbing dyskinesia, corresponding to scores 2-4 in the specific items of MDS-UPDRS III, such as to affect the psychometric evaluation; h) auditory and/or visual dysfunctions impairing the patient´s ability to perform cognitive tests.

Sponsors & Collaborators

• Ospedale Generale Di Zona Moriggia-Pelascini: lead
• Ospedale di Vipiteno-Sterzing (SABES-ASDAA): collaborator

Study Sites (1)

"Moriggia Pelascini" Hospital

Gravedona E Uniti, Como, 22015, Italy

Location

Related Publications (1)

• Ortelli P, Ferrazzoli D, Versace V, Cian V, Zarucchi M, Gusmeroli A, Canesi M, Frazzitta G, Volpe D, Ricciardi L, Nardone R, Ruffini I, Saltuari L, Sebastianelli L, Baranzini D, Maestri R. Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test. NPJ Parkinsons Dis. 2022 Apr 11;8(1):42. doi: 10.1038/s41531-022-00304-z.

  PMID: 35410449 DERIVED

MeSH Terms

Conditions

Parkinson Disease; Parkinson Disease, Secondary; Multiple System Atrophy; Supranuclear Palsy, Progressive

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Primary Dysautonomias; Autonomic Nervous System Diseases; Ophthalmoplegia; Ocular Motility Disorders; Cranial Nerve Diseases; Tauopathies; Paralysis; Neurologic Manifestations; Eye Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 21, 2021
• First Posted: April 26, 2021
• Study Start: January 1, 2017
• Primary Completion: February 1, 2020
• Study Completion: August 31, 2020
• Last Updated: May 12, 2021

Record last verified: 2021-05

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)